Experimental therapy plus chemo for borderline resectable esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called QL1706 combined with standard chemotherapy to see if it can shrink esophageal tumors that are hard to remove with surgery alone. It’s for people who haven’t had any treatment yet and are well enough for daily activities.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must be a type called squamous cell carcinoma of the esophagus.
- Your tumor is stage T4a, or nearby lymph nodes are suspicious or enlarged, or cancer has spread to lymph nodes above your collarbone.
- You haven’t had any prior treatment for your cancer.
- You must be at least 18 years old.
- You need to be able to take care of yourself and be up and around (ECOG score 0 or 1).
- You must agree to sign a consent form after understanding the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding immunotherapy to standard chemoradiation (chemotherapy plus radiation) can help preserve the esophagus and avoid surgery in people with resectable esophageal cancer. It aims to see if this combination is safer and more effective than current treatment.
This trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (given before surgery) can help shrink stage II/III esophageal cancer. The goal is to make surgery more likely to remove all cancer and improve outcomes.
This trial tests adding an immunotherapy drug (QL1706) to standard chemotherapy before surgery for a certain type of esophageal cancer. The goal is to see if the combination works better than chemotherapy alone at shrinking the tumor and improving surgery outcomes.
This trial tests whether combining a new immunotherapy drug (adebrelimab) with standard chemotherapy can help shrink borderline resectable esophageal squamous cell carcinoma before surgery. The goal is to make tumors easier to remove and improve survival.
This study tests a new treatment approach for patients with advanced esophageal cancer whose disease progressed or didn't respond to initial chemotherapy and immunotherapy. The goal is to see if this new treatment can help shrink tumors and improve outcomes for patients who cannot have surgery.
This trial tests a drug called Adebrelimab combined with chemotherapy before surgery for esophageal cancer. It aims to shrink the tumor and make it easier to remove completely.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.